NCT07739485招募中1 期
A Dose-Finding Study of Paclitaxel Oral Solution in Neoadjuvant Therapy for Patients With Triple Negative Breast Cancer
Liu Shu1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2026年7月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Maximum Tolerated Dose(MTD)
研究概览
简要总结
This is a multicenter, open-label, dose-escalation trial using a backfill Bayesian optimal interval (BF-BOIN) design to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) for paclitaxel oral solution followed by epirubicin plus cyclophosphamide therapy. Eligible triple-negative breast cancer patients are enrolled in three cohorts at oral paclitaxel dose levels 1-3 (125, 150, 175 mg/m²).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female, aged 18 to 70 years.
- •Histologically confirmed invasive breast cancer by core needle biopsy; clinical stage T1c-4, N0-3, M0 per the AJCC 8th edition breast cancer staging system (T1cN0M0 excluded).
- •Triple-negative breast cancer (TNBC) is defined as ER <1%, PR <1%, and HER2-negative [IHC 0, IHC 1+, or IHC 2+ with FISH-negative].
- •Left ventricular ejection fraction (LVEF) ≥ 50%.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Adequate organ function assessed within 14 days prior to first dose of study drug, without blood transfusion or growth-factor support, meeting the following:
- •Hematology: absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; platelet count (PLT) ≥ 100 × 10⁹/L; hemoglobin (Hb) ≥ 90 g/L.
- •Blood chemistry: total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 × ULN; blood urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5 × ULN; creatinine clearance (CrCl) ≥ 50 mL/min by the Cockcroft-Gault formula.
- •Voluntary participation with signed informed consent, good compliance, and willingness to attend follow-up.
排除标准
- •History of prior invasive breast cancer.
- •Bilateral breast cancer, or inflammatory breast cancer (e.g., erythema and/or skin involvement and/or pathological evidence of tumor cells in dermal lymphatics).
- •Prior excisional and/or incisional biopsy of the primary tumor and/or axillary lymph nodes.
- •Prior systemic therapy for breast cancer.
- •History of life-threatening hypersensitivity reaction, or known allergy to any component of the study drug.
- •Participation in another drug or medical device clinical trial within 4 weeks prior to first dose, with receipt of investigational product or device.
- •Major surgery within 28 days prior to first dose, or planned major surgery during the study.
- •Other malignancy within the past 5 years (except cervical carcinoma in situ, non-melanoma skin cancer, localized prostate cancer, and ductal carcinoma in situ).
- •Active tuberculosis or other serious infectious disease, including but not limited to bacteremia, severe infectious pneumonia, or other severe infection requiring systemic therapy.
- •History of immunodeficiency or other autoimmune disease, including but not limited to HIV infection (positive HIV antibody), systemic lupus erythematosus, rheumatoid arthritis, or history of organ transplantation.
- •History of any of the following cardiovascular/cerebrovascular diseases: (1) unstable angina; (2) clinically significant or medication-requiring arrhythmia; (3) myocardial infarction within 6 months; (4) heart failure, or second-degree or higher atrioventricular block; (5) cerebral infarction (except lacunar infarction) or cerebral hemorrhage within 6 months.
- •Uncontrolled hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg despite regular antihypertensive medication), or history of hypertensive crisis or hypertensive encephalopathy.
- •Uncontrolled concurrent illness or condition (including significant psychiatric or social condition) that, in the investigator's judgment, may affect compliance with study procedures.
- •Requirement for long-term use of proton pump inhibitors or H2 receptor antagonists during the study; or use of strong inducers or inhibitors of CYP3A4 or CYP2C8 within 2 weeks prior to first study-drug administration.
- •In the investigator's judgment, subjects unsuitable or unwilling to take oral study drug: (1) clinically significant or uncontrolled congenital or acquired gastrointestinal disease; (2) diagnosed disease that may affect administration, gastrointestinal transit, or absorption of the study drug, or adherence to oral study drug, including intestinal obstruction and inflammatory bowel disease (Crohn's disease and ulcerative colitis), peptic ulcer, uncontrolled nausea, vomiting, or diarrhea; (3) presence or suspected impairment of bile secretion.
- •Pregnant or lactating women; women of childbearing potential with a positive pregnancy test at screening; or those unwilling to use effective contraception throughout the study and for 3 months after the last dose.
- •Any other condition that, in the investigator's opinion, makes the subject unsuitable for enrollment.
研究组 & 干预措施
Dose-level 1 cohort
Experimental
The dose of paclitaxel oral solution is 125mg/m2.
干预措施: Epirubicin and cyclophosphamide followed by paclitaxel oral solution (Drug)
Dose-level 2 cohort
Experimental
The dose of paclitaxel oral solution is 150mg/m2.
干预措施: Epirubicin and cyclophosphamide followed by paclitaxel oral solution (Drug)
Dose-level 3 cohort
Experimental
The dose of paclitaxel oral solution is 175mg/m2.
干预措施: Epirubicin and cyclophosphamide followed by paclitaxel oral solution (Drug)
结局指标
主要结局
Maximum Tolerated Dose(MTD)
时间窗: Up to approximately 30 weeks
次要结局
- total Pathological Complete Response(tpCR)(Up to approximately 30 weeks.)
- Overall Response Rate(ORR)(Up to approximately 30 weeks.)
研究者
Liu Shu
Professor
The Affiliated Hospital Of Guizhou Medical University
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding StudyHER2 + Breast CancerNCT07739511Liu Shu30
招募中
2 期
Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion StudyAdvanced Breast CancerNCT07602907Zhejiang Cancer Hospital73
进行中（未招募）
不适用
Bioequivalence (BE) study of Paclitaxel 100mg/vial with ABRAXANE® 100mg/vial in subject with metastatic Breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy.CTRI/2024/03/064383Anbison Lab. Co., Ltd.32
招募中
2 期
Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian CancerOvarian CancerNCT07261683Obstetrics & Gynecology Hospital of Fudan University20
尚未招募
1 期
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD)NCT07462455Xiamen Amoytop Biotech Co., Ltd.24